B. Metzler Seel. Sohn & Co. Ag Atara Biotherapeutics, Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.31 $69,487 - $113,841	-49,282 Reduced 50.0%	49,282 $72,000
Q2 2023 Aug 11, 2023	BUY	$1.5 - $3.04 $73,923 - $149,817	49,282 Added 100.0%	98,564 $158,000
Q4 2022 Feb 13, 2023	BUY	$2.85 - $5.18 $26,510 - $48,184	9,302 Added 23.27%	49,282 $161,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $67,998 - $208,289	23,859 Added 148.0%	39,980 $151,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $75,607 - $158,630	16,121 New	16,121 $126,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $802M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.